AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00313820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
Trial: NCT00265889
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg IV over 2 hours x 2 days
Trial: NCT00860379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV saline as placebo
Trial: NCT03519854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl administered as a fast IV bolus dose (within 30 seconds).
Trial: NCT03519854
Drug: Esmeron®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmeron® administered at 0.6 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
Trial: NCT01515748
Drug: S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Trial: NCT01458197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, qd, 12 weeks
Trial: NCT00506064
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.15 mg/kg by mouth (PO) Daily
Trial: NCT01821261
Drug: Mouth Rinse 500347078842
RxNorm normalized name: phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 ml of mouth rinse 500347078842 for 60 seconds, twice daily
Trial: NCT01821261
Drug: Toothpaste 035000513007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately one inch of toothpaste 035000513007, twice daily
Trial: NCT02535104
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control
Trial: NCT00541450
Drug: Matching Placebo to Sita/Met FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo to Sita/Met FDC - 50/500 mg b.i.d. for 4 weeks and then 50/1000 mg b.i.d. orally for a 28-wk treatment period (Week 12 to Week 40).
Trial: NCT00290589
Drug: Intramuscular methylprednisolone acetate
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular methylprednisolone acetate 160mg
Trial: NCT04648540
Drug: Fentanyl 1 mic/kg/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Group II (OA) patients will receive a continuous infusion of Fentanyl (1 mic/kg/h) Morphine 0.1 mg/kg PRN will be administered every 8 hours for postoperative analgesia
Trial: NCT00137566
Drug: acetaminophen (paracetamol)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol tablets, 50 mg/kg/day for 3 days.
Trial: NCT02291679
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01535768
Drug: Aqueous Suppressant Eye Drops
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous suppressant eye drops added stepwise to achieve IOP between 7-10mmHg. First, a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID).~Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID).~Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)
Trial: NCT00456833
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03583749
Drug: Subcutaneous (SC) route for antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving one of the three antibiotics by SC route without any randomization because the route will be chosen before inclusion by the physician in charge.
Trial: NCT03583749
Drug: Intravenous (IV) route for antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving one of the three antibiotics by IV route without any randomization because the route will be chosen before inclusion by the physician in charge.
Trial: NCT03153579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing mannitol looking identical to LSD
Trial: NCT01068158
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: up to 4 ounces of topical vehicle control to head and scalp on day 1.
Trial: NCT03620253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the placebo group will receive 100 mg placebo capsules for 1 week, followed by 200 mg for 7 weeks, which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
Trial: NCT02452268
Drug: NIZ985
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks
Trial: NCT02452268
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
Trial: NCT02276222
Drug: Spiriva® 18 mcg QD Handihaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Trial: NCT02617017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
Trial: NCT01951625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00642187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00326131
Drug: Oral Taxane
RxNorm normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02598505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00785408
Drug: AC2307
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous, twice daily, low dose
Trial: NCT00785408
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous, twice daily, low dose
Trial: NCT00785408
Drug: AC2307
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous, twice daily, middle dose
Trial: NCT00785408
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous, twice daily, middle dose
Trial: NCT00785408
Drug: AC2307
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous, twice daily, high dose
Trial: NCT00785408
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous, twice daily, high dose
Trial: NCT03673696
Drug: HEC74647PA Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule administered orally once daily
Trial: NCT02706119
Drug: Regular insulin added to TPN bag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
Trial: NCT01170221
Drug: TR-701 FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.
Trial: NCT03329287
Drug: SSRIs and/or SNRIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs and/or SNRIs at a recommended dosage.
Trial: NCT01047592
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo,oral, for 12 weeks
Trial: NCT00054236
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide IV over 2 hours on days -3 to -2
Trial: NCT00559650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be standard therapy and placebo versus, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
Trial: NCT00004014
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin HCl liposome IV over 45 minutes every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then every 9 weeks thereafter.
Trial: NCT00086736
Drug: oral eflornithine placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00833560
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In Part 1, cyclophosphamide with dose ranging from 900 to 1500 mg will be administered intravenously on Day 1 of each 21 day cycle for 3 cycles to determine optimal dose. In Part 2, optimal dose determined in Part 1 will be administered on Day 1 of each 21 day cycle for 3 cycles.
Trial: NCT00999466
Drug: AZD8848
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.
Trial: NCT00999466
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.
Trial: NCT00649168
Drug: Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
Trial: NCT00477230
Drug: Standard Anti-arrhythmic Drug (AAD) Therapy
RxNorm normalized name: INVESTIGATIONAL ANTI-NEOPLASTIC DRUGS, GENE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication as prescribed by physician.
Trial: NCT00225056
Drug: docetaxel and capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01229241
Drug: local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: postoperative 48h epidural continuous infusion,~1. ropivacaine 0,2% (250ml)+ sufentanil 0,75mcg/ml~2. levobupivacaine 0,125% (250ml)+ sufentanil 0,75mcg/ml
Trial: NCT01791725
Drug: ELND005
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01791725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00738946
Drug: Intermittent preventive treatment with AQ+ SP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (10 mg/kg over 3 days) and Sulfadoxine Pyrimethamine (25 mg of sulfadoxine + 1.25 mg of pyrimethamine per kg in a single dose) or placebo administered over 3 rounds of one month interval
Trial: NCT00332319
Drug: GW679769
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00776321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03574415
Drug: DWP14012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 tablets
Trial: NCT03574415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 placebo-matching tablets
Trial: NCT00992602
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00002481
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003203
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03530930
Drug: Comarum Palustre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comarum Palustre tablets 500 mg BID, 1 month
Trial: NCT01313702
Drug: polipillV1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
Trial: NCT01313702
Drug: polipillV2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
Trial: NCT01313702
Drug: usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the drugs used in clinical practice, defined by physician
Trial: NCT05682911
Drug: Zingiber officinale L. tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zingiber officinale L. tablets 500mg twice daily
Trial: NCT05682911
Drug: Simvastatin 20mg
RxNorm normalized name: SIMVASTATIN 20MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20mg once a day for 2 months
Trial: NCT02096328
Drug: POL7080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT00892112
Drug: Intravenous Immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 gr/kg body weight of intravenous immunoglobulin product Nanogam® administered as 0.5 gr/kg IV over a period of 6 hours on each of 4 consecutive days
Trial: NCT00892112
Drug: plasma volume expander
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml/kg BW will be administrated on four consecutive days.
Trial: NCT01487317
Drug: placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One transdermal patch of placebo per day from randomization to day 14 Before day 14: end of treatment if DRS R-98 severity \< 10 during 2 consecutive days, At day 14 if DRS R-98 severity ≥ 10: One transdermal patch of placebo per day from day 14 to day 30 if DRS R-98 severity \< 10, the placebo treatment will be stopped
Trial: NCT01030861
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Teplizumab
Trial: NCT01686555
Drug: ABT-199
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04402866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be administered by inhalation
Trial: NCT02362529
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg and 100 mg capsule, oral administration
Trial: NCT02362529
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg and 200 mg capsules, oral administration.
Trial: NCT03351972
Drug: Klean Prep
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomised to use polyethylene glycol will follow either routine guidance of taking the bowel prep the night before their capsule endoscopy or receive guidance that they should split their dose between the night before and the morning of the procedure
Trial: NCT02660710
Drug: R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maximum of 6-8 cycles of R-CHOP over 18-24 weeks
Trial: NCT02816151
Drug: full dose at 16 UI/kg for Dysport or 6,5 UA/kg for Botox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
Trial: NCT02816151
Drug: half dose at 8 UI/kg for Dysport or 3,25 UA/kg for Botox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
Trial: NCT00754338
Drug: Alcon Opti-Free® RepleniSH® with Supraclens®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed Multipurpose Disinfecting Care System + Marketed contact lens protein remover
Trial: NCT00754338
Drug: Alcon Opti-Free® RepleniSH®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed Multipurpose Disinfecting Care System
Trial: NCT00754338
Drug: B&L ReNu MultiPlus™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed Multipurpose Disinfecting Care Systems
Trial: NCT02351219
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04358081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03103087
Drug: Estradiol/norethindrone acetate
RxNorm normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
Trial: NCT01256411
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received LCZ696 200 mg as the starting dose with optional down titration to 100 mg for tolerance and optional up titration to 400 mg for adequate blood pressure control.
Trial: NCT03128996
Drug: RIC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days -60 to -21: hydroxyurea (30mg/kg/day po) \>6hrs prior to 1st dose: alemtuzumab (3mg IV) Day -21: alemtuzumab (10mg IV or S/C) Day -20: alemtuzumab (15mg IV or S/C) (10mg if \< 10kg) Day -19: alemtuzumab (20mg IV or S/C) (10mg if \< 10kg) Days -8 to -4: fludarabine (30mg/m2/day IV) Day -4: thiotepa (8mg/kg IV) Day -3: melphalan (140mg/m2) Days -2 to -1: rest days/no therapy Day 0: bone marrow transplant
Trial: NCT03128996
Drug: GVHD prophylaxis regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day +3 to +4: cyclophosphamide (50mg/kg/day IV) Day +5: Start of tacrolimus \& Start of mycophenolate mofetil (MMF) Days +5, +14, +30, +60, +90: abatacept (IND) (10mg/kg/day IV) Days +120 to +390: abatacept (IND) monthly (5mg/kg/day IV)
Trial: NCT03103087
Drug: Estradiol/norethindrone acetate placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
Trial: NCT01279499
Drug: Propofol- Remifentanyl
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (doses based on ideal body weight).~Every rise of BP or HR \> 15% of baseline will be followed by a Remifentanyl bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remifentanyl from 0.1 to 1.0 μg/kg/min
Trial: NCT01279499
Drug: Propofol, Remifentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW). General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (ideal body weight).~The depth of anesthesia will be adjusted so as to accomplish a BIS score between 40 and 50 Every rise of BP or HR \> 15% of baseline will be followed by a Remi bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remi from 0.1 to 1.0 μg/kg/min
Trial: NCT00232492
Drug: Placebo males
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline bolus (Placebo-control) males
Trial: NCT00232492
Drug: Placebo females
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline bolus (Placebo-control) females
Trial: NCT01292239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule taken by mouth once daily for 12 weeks
Trial: NCT01292239
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-mg capsule taken by mouth once daily for 12 weeks
Trial: NCT00908570
Drug: estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml vaginal cream (1.0 mg estriol/1 ml cream), 3 days/week for approximately 2 months.
Trial: NCT00908570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream
Trial: NCT00459563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once a week for 3 weeks
Trial: NCT00404287
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04491240
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
Trial: NCT00729404
Drug: Ethinylestradiol/Gestodene (BAY86-5016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)
Trial: NCT04086602
Drug: IZD334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Drug
Trial: NCT04086602
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Match